Glioma

FACS analysis showed loss of co-stimulatory CD80, an immune synapse component, following B3gat1 knockdown. These results suggest that loss of HNK-1 expression contributes to tumor immune escape through loss of immune recognition and attack via downregulation of tumor cell surface co-stimulatory molecules, leading to reduced CD8+ T-cell activation and immune synapse formation, and increased T-cell apoptosis.

P=N/A, N=228, Not yet recruiting, Institut du Cancer de Montpellier - Val d'Aurelle | Trial completion date: Apr 2028 --> Oct 2028 | Trial primary completion date: Oct 2026 --> Apr 2027

P1, N=12, Not yet recruiting, Neonc Technologies, Inc. | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Oct 2026

P1, N=11, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | N=30 --> 11

Sirtinol was detected in the brains of sirtinol-treated mice, suggesting blood brain barrier penetrance. Conclusions : Based on our results, sirtinol shows promise as a selective, redox-modulating therapeutic for DIPG that enhances oxidative stress and interferes with DNA repair.

P1/2, N=30, Enrolling by invitation, Beijing Bio-Targeting Therapeutics Technology Co., Ltd | Trial completion date: Aug 2026 --> Jul 2027 | Trial primary completion date: Aug 2026 --> Jul 2027

Western blot analysis confirmed that HDAC inhibition increased AcH3K9 protein levels. Further, studies in in vivo xenograft model and allograft C6 Wistar rat model revealed strong antitumour activity, suggesting that compound 3B is a promising therapeutic candidate for glioblastoma treatment.

These data point out the potential of miR21 as early biomarker for glioma diagnosis and disease monitoring, emphasizing the role of non-tumoral cells, particularly microglia, as rapidly reacting elements in the context of gliomas.

A general drug resistance to TRK-inhibition was documented. This study addresses the complex and adaptive nature of pediatric epithelioid glioblastomas and highlights the need for continued molecular profiling from relapses and various tumor regions to enable multitarget treatment approaches.

This work pioneers the integration of human ferritin nanocages with magnetic nanocores for precise, non-invasive cancer imaging, offering a transformative approach to early tumor detection and monitoring, and addressing critical safety and sensitivity limitations of existing MRI contrast agents.